DNA Q3 2022 Earnings — Ginkgo Bioworks Holdings, Inc. Revenue & Financial Results | Market Cap Arena

DNAGinkgo Bioworks Holdings, Inc.

$418M

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$66M-14.4% YoY

Gross Profit

$42M62.9% margin

Operating Income

-$655M-986.4% margin

Net Income

-$670M-1009.3% margin

EPS (Diluted)

$-16.44

QoQ Revenue Growth

-54.1%

Cash Flow

Operating Cash Flow

-$28M

Free Cash Flow

-$42M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.9B

Total Liabilities

$431M

Stockholders' Equity

$1.4B

Cash & Equivalents

$1.3B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$66M	$78M	-14.4%
Gross Profit	$42M	$55M	-24.5%
Operating Income	-$655M	-$27M	-2355.5%
Net Income	-$670M	-$102M	-557.8%

Revenue Segments

Service

$37M55%

Foundry Revenue

$25M37%

Product

$5M8%